Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

As AbbVie Inc. ABBV looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant’s future growth, analysts say. When ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...